GSK will pay $90 million to settle diabetes drug allegations

Share this article:
GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). As a result of the settlement, GSK must change the way it promotes its diabetes drugs, including Avandia. However, the company did not admit to “any wrongdoing or liability of any kind.” The states charged that GSK did not report some Avandia safety data. They also said the drug manufacturer violated consumer protection laws when it misrepresented heart attack risk with the drug, as well as the safety of its use, alone or in combination with other drugs.

Share this article:

More in Products

Bertlesmann buys Relias Learning

Bertelsmann, a media company based in Germany, said last week it is buying Relias Learning from its current owners, Vista Equity Partners and LLR Partners.

Acuity Brands introduces LED collection

Acuity Brands introduces LED collection

Acuity Brands says its new CanoeTM LED Pendant and Sconce Collection from Winona Lighting® can meet the needs of designers in unique spaces.

SwimEx debuts Triton Pool

SwimEx debuts Triton Pool

SwimEx Inc. has announced the Triton, the newest member of its line of fitness and therapy pools. It is available for the commercial and residential markets.